See more : Datatec Limited (DTTLY) Income Statement Analysis – Financial Results
Complete financial analysis of Enliven Therapeutics, Inc. (ELVN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Enliven Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- CTX Virtual Technologies, Inc. (CTXV) Income Statement Analysis – Financial Results
- Nissan Shatai Co., Ltd. (7222.T) Income Statement Analysis – Financial Results
- Landmark Cars Limited (LANDMARK.BO) Income Statement Analysis – Financial Results
- Travis Perkins plc (TPK.L) Income Statement Analysis – Financial Results
- AmeriWorks, Inc. (AWKS) Income Statement Analysis – Financial Results
Enliven Therapeutics, Inc. (ELVN)
About Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its pipeline of small molecule kinase inhibitors include ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial has been activated to evaluate people with cancers harboring an abnormal HER2 gene. The company is based in Boulder, Colorado.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 297.00K | 622.00K | 99.00K | 97.00K | 33.00K | 0.00 | 0.00 |
| Gross Profit | -297.00K | -622.00K | -99.00K | -97.00K | -33.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 64.57M | 31.02M | 20.47M | 8.24M | 19.01M | 8.24M | 7.92M |
| General & Administrative | 18.96M | 7.77M | 4.29M | 1.08M | 5.11M | 2.44M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | -33.00K | 0.00 | 0.00 |
| SG&A | 18.96M | 7.77M | 4.29M | 1.08M | 5.07M | 2.44M | 987.00K |
| Other Expenses | 0.00 | 0.00 | 0.00 | -9.68M | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.08M | 10.68M | 8.91M |
| Cost & Expenses | 83.53M | 38.79M | 24.76M | 9.32M | 24.12M | 10.68M | 8.91M |
| Interest Income | 11.97M | 1.13M | 22.00K | 31.00K | 578.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 297.00K | 215.00K | 115.00K | 97.00K | 33.00K | -660.00K | 0.00 |
| EBITDA | -81.93M | -38.58M | -24.65M | -9.27M | -23.43M | -11.34M | 221.00K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -83.53M | -38.79M | -24.76M | -9.32M | -24.12M | -10.68M | -8.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 11.95M | 1.13M | 22.00K | -9.65M | 653.00K | -660.00K | 9.13M |
| Income Before Tax | -71.58M | -37.66M | -24.74M | -18.97M | -23.46M | -11.34M | 221.00K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 88.00K | -22.00K | -31.00K | 653.00K | -821.14K | 221.00K |
| Net Income | -71.58M | -37.75M | -24.72M | -18.94M | -23.46M | -11.34M | 0.00 |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| EPS Diluted | -2.01 | -6.03 | -3.17 | -14.14 | -5.43 | -2.62 | 0.00 |
| Weighted Avg Shares Out | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
| Weighted Avg Shares Out (Dil) | 35.55M | 6.25M | 7.81M | 3.48M | 4.32M | 4.32M | 4.32M |
Imara To Start Testing Tovinontrine In Heart Failure Patients
The FDA signed off Imara Inc's (NASDAQ: IMRA) investigational new drug (IND) application for tovinontrine (IMR-687) in heart failure with preserved ejection fraction (HFpEF). The Company plans to initiate a Phase 2 trial in Q2 of 2022 to evaluate tovinontrine in patients 45...
Imara to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat subjects suffering from rare inherited genetic disorders of hemoglobin and other serious diseases, today announced that...
Imara Changes Primary Endpoint In Mid-Stage Sickle Cell Disease Trial
Imara Inc (NASDAQ: IMRA) has announced a change to the primary endpoint for the Ardent Phase 2 trial of tovinontrine (IMR-687) in sickle cell disease. Imara is a biopharmaceutical company focused on therapeutics for rare inherited genetic disorders of hemoglobin.
7 Penny Stocks to Book Profits on Before 2022
Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors.
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
IMARA Inc. (IMRA) CEO Rahul Ballal on Q3 2021 Results - Earnings Call Transcript
Imara to Present Clinical and Preclinical Data at the American Society of Hematology (ASH) Annual Meeting 2021
Tovinontrine (IMR-687) VOC data in patients with sickle cell disease from ongoing Phase 2a open-label extension study and preclinical models of beta-thalassemia to be presented
Imara to Participate in Upcoming Investor Conferences
SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference SVB Leerink CybeRx Series and 2021 Cantor Virtual Global Healthcare Conference
Imara to Present at Upcoming Investor Conferences
Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global Healthcare Conference Citi 16th Annual BioPharma Virtual Conference, H.C. Wainwright 23rd Annual Global Investment Conference and Morgan Stanley 19th Annual Global...
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
IMARA's (IMRA) CEO Rahul Ballal on Q2 2021 Results - Earnings Call Transcript
Imara Reports Second Quarter 2021 Financial Results and Business Highlights
Accelerated enrollment in Phase 2b trials in sickle cell disease and beta-thalassemia; interim analyses expected in fourth quarter of 2021
Source: https://incomestatements.info
Category: Stock Reports